1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
HLB PANAGENE Co. LTD.

HLB PANAGENE Co. LTD.

KKRX:046210
1,393.00
KRW
-1.00
(-0.07%)
-81.01EPS
106.40BMarket Cap
HLB PANAGENE Co. LTD.
KRX:046210
(Korea Stock Exchange)

Recent

price

1,393.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
1,389.43
1,668.47
129.62
162.81
187.23
216.22
245.8
234.84
241.29
247.24
506.25
486.8
442.75
340.93
319.07
337.02
331.09
Revenue per Share
-191
-64.1
-296
-184
-82
-23
-55
-221
-129
109
153
155
70
-134
-47
-70
-81.79
Basic EPS, GAAP
-145.69
-235.19
161.22
-52.78
-147.42
-54.26
-137.99
-220.35
5.62
2.94
118.53
173.77
93.72
-18.62
-11.59
-56.92
-68.67
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
667.46
641.47
359.14
332.47
331.78
332.25
710.77
621.08
508.94
628.71
780.11
928.65
986.08
1,550.39
1,788.94
1,591.13
1,639.22
Book Value per Share
407.34
330.18
27.29
-1.78
6.92
2.23
380
517.36
502.79
622.3
772.05
919.58
978.14
1,543.41
1,564.73
1,499.6
1,548.38
Tangible Book Value per Share
24
25
25
26
27
27
28
31
32
32
32
32
32
36
41
45
44
Basic Weighted Avg Shares
33,712
41,453
3,215
4,216
5,011
5,920
6,961
7,395
7,704
7,950
16,267
15,601
14,171
12,252
13,197
15,050
14,640
Sales/Revenue/Turnover
-7.52
-3.84
-71.66
-84.35
-18.81
2.66
-10.76
-43.28
-17.4
-7.65
31.65
26.7
11.14
-15.01
-10.31
-22.86
-23.61
Operating Margin (%)
1,295
1,104
1,020
897
1,097
1,021
827
60
1,187
1,333
1,323
1,330
1,213
999
1,336
1,689
1,712
Depreciation Expense
-4,634
-1,592
-7,342
-4,765
-2,195
-630
-1,558
-6,959
-4,119
3,505
4,916
4,967
2,240
-4,816
-1,944
-3,126
-3,617
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-13.75
-3.84
-228.37
-113.02
-43.8
-10.64
-22.38
-94.11
-53.46
44.09
30.22
31.84
15.81
-39.3
-14.73
-20.77
-24.7
Profit Margin (%)
3,468
9,450
3,305
-3,866
3,578
3,903
6,541
8,228
6,498
9,625
17,585
22,650
24,595
55,766
40,751
23,561
25,285
Working Capital
1,680
10,774
11,266
- -
7,344
8,053
- -
- -
- -
8
12
43
129
89
3,974
1,509
1,364
LT Debt
16,582
15,938
8,923
8,912
8,894
8,906
21,098
19,839
16,303
20,205
25,070
29,844
31,689
63,573
76,128
72,435
74,622
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3.6
24.28
15.78
5.25
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.2
21.7
18.07
7.27
- -
- -
- -
- -
Return on Capital (%)
-26.86
-9.79
-59.07
-53.43
-24.65
-7.08
-10.38
-34
-22.79
19.2
21.72
18.09
7.28
-10.11
-2.78
-4.21
-4.75
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
13,815
14,074
4,997
LT Borrowings
1,638
1,471
1,303
LT Finance Leases
28
38
61
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
45
Market Capitalization
75,271
78,937
106,401

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
49,237
42,264
31,960
Cash, Cash Equivalents & STI
41,460
33,841
24,560
Accounts Receivable, Net
3,301
4,274
3,327
Inventories
3,802
3,182
3,273
Total Current Liabilities
22,230
18,703
6,675
Payables & Accruals
- -
- -
- -
ST Debt
13,815
14,074
4,997
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.18%
28.15%
-4.85%
Free Cash Flow
430.32%
55.95%
430.36%
Net Income, GAAP
-5.92%
-73.53%
60.8%
Sales/Revenue/Turnover
13.08%
-1.01%
14.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,407
2,464
3,852
3,474
13,197
2025
3,539
3,640
3,636
4,235
15,050
2026
3,130
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14
-89
-2
28.68
-47
2025
-14
27
-4
-78.91
-70
2026
-23.64
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
Medtronic plc. (NYSE:MDT)
Business
HLB PANAGENE Co., Ltd. is a South Korea-based biotechnology and molecular diagnostics company that develops, manufactures, and commercializes peptide nucleic acid (PNA)-based in vitro diagnostic products and high-purity biomaterials for clinical and research applications. Founded in 2001 and headquartered in Daejeon, South Korea, the company operates as a key diagnostic subsidiary of the HLB Group, serving medical institutions, reference laboratories, academic research centers, and biopharmaceutical manufacturers across South Korea, the Asia-Pacific region, North America, and Europe. HLB PANAGENE provides an integrated portfolio of molecular diagnostic solutions and specialized synthesis services, comprising PANAMutyper diagnostic kits designed for ultrasensitive somatic mutation detection and circulating cell-free DNA (cfDNA) liquid biopsy analysis; PNAClamp real-time PCR mutation detection kits targeting critical oncology biomarkers including EGFR, KRAS, NRAS, BRAF, and PIK3CA for lung, colorectal, gastric, and thyroid cancers; infectious disease diagnostic test kits for human papillomavirus (HPV), sexually transmitted pathogens, and respiratory viruses; custom-manufactured PNA oligomers and high-purity PNA monomers utilized in gene regulation, antisense drug development, and biosensor technologies; and associated molecular biology reagents alongside automated diagnostic testing systems. In recent strategic developments, the company was acquired by an HLB Group-led consortium and officially changed its corporate name from Panagene Inc. to HLB PANAGENE Co., Ltd. to accelerate synergies with HLB Group's global anticancer therapeutics portfolio, particularly through the development of companion diagnostics (CDx). Additionally, the company has expanded its technological capabilities into next-generation sequencing (NGS) and artificial intelligence-integrated genomic analysis, secured regulatory clearances for novel cancer mutation panels, and established international distribution partnerships to expand its presence across overseas healthcare markets.